GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) and MacroGenics (NASDAQ:MGNX – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Valuation and Earnings
This table compares GE HealthCare Technologies and MacroGenics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GE HealthCare Technologies | $19.67 billion | 1.70 | $1.99 billion | $4.88 | 15.04 |
| MacroGenics | $149.96 million | 0.71 | -$66.97 million | ($0.57) | -2.96 |
Insider & Institutional Ownership
82.1% of GE HealthCare Technologies shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 0.3% of GE HealthCare Technologies shares are held by company insiders. Comparatively, 13.0% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares GE HealthCare Technologies and MacroGenics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GE HealthCare Technologies | 11.22% | 23.93% | 6.29% |
| MacroGenics | -21.99% | -40.24% | -14.62% |
Risk & Volatility
GE HealthCare Technologies has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for GE HealthCare Technologies and MacroGenics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GE HealthCare Technologies | 0 | 6 | 6 | 0 | 2.50 |
| MacroGenics | 1 | 4 | 1 | 1 | 2.29 |
GE HealthCare Technologies currently has a consensus price target of $85.20, indicating a potential upside of 16.11%. MacroGenics has a consensus price target of $3.60, indicating a potential upside of 113.02%. Given MacroGenics’ higher possible upside, analysts clearly believe MacroGenics is more favorable than GE HealthCare Technologies.
Summary
GE HealthCare Technologies beats MacroGenics on 10 of the 15 factors compared between the two stocks.
About GE HealthCare Technologies
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
About MacroGenics
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
